
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7174042/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Body composition, adipokines, FGF23-Klotho and bone in kidney transplantation: Is there a link?. Journal of Nephrology, 2022, 35, 293-304.	2.0	6
2	The Role of Uric Acid in the Acute Myocardial Infarction: A Narrative Review. Angiology, 2022, 73, 9-17.	1.8	11
3	Epidemiology of biopsy-proven glomerulonephritis in the past 25Âyears in the North-Eastern area of Romania. International Urology and Nephrology, 2022, 54, 365-376.	1.4	2
4	Effect of sodium–glucose cotransporter 2 inhibitors on hemoglobin and hematocrit levels in type 2 diabetes: a systematic review and meta-analysis. International Urology and Nephrology, 2022, 54, 827-841.	1.4	20
5	Evaluation of cardiovascular events and progression to end-stage renal disease in patients with dyslipidemia and chronic kidney disease from the North-Eastern area of Romania. International Urology and Nephrology, 2022, 54, 647-659.	1.4	5
6	Magnesium and kidney disease. , 2022, , 345-351.		0
7	Bone Disease and Diabetes. , 2022, , 361-379.		Ο
8	Revisiting risk prediction tools for death and end-stage renal disease in older patients with advanced chronic kidney disease: a prospective study. International Urology and Nephrology, 2022, , 1.	1.4	2
9	Fatty kidney: A possible future for chronic kidney disease research. European Journal of Clinical Investigation, 2022, 52, e13748.	3.4	6
10	Sodium–glucose cotransporter inhibition in polycystic kidney disease: fact or fiction. CKJ: Clinical Kidney Journal, 2022, 15, 1275-1283.	2.9	7
11	The role of body mass index on IgA nephropathy prognosis: a systematic review and meta-analysis. International Urology and Nephrology, 2022, , 1.	1.4	0
12	Pulmonary Arterial Hypertension and Adverse Outcomes after Kidney Transplantation: A Systematic Review and Meta-Analysis. Journal of Clinical Medicine, 2022, 11, 1944.	2.4	6
13	The Usefulness of Assessing Heart Rate Variability in Patients with Acute Myocardial Infarction (HeaRt-V-AMI). Sensors, 2022, 22, 3571.	3.8	2
14	Coronary artery disease in dialysis patients: evidence synthesis, controversies and proposed management strategies. Journal of Nephrology, 2021, 34, 39-51.	2.0	4
15	"Celebrating old age†an obsolete expression during the COVID-19 pandemic? Medical, social, psychological, and religious consequences of home isolation and loneliness among the elderly. Archives of Medical Science, 2021, 17, 285-295.	0.9	30
16	Efficiency of Hypertonic Saline in the Management of Decompensated Heart Failure: A Systematic Review and Meta-Analysis of Clinical Studies. American Journal of Cardiovascular Drugs, 2021, 21, 331-347.	2.2	6
17	â€~ <i>Will the king ever be dethroned</i> ?' The relationship and the future of oral anticoagulation therapy versus LAA closure devices. Expert Review of Cardiovascular Therapy, 2021, 19, 1-4.	1.5	2
18	Health-related quality of life in patients with chronic kidney disease. Expert Review of Pharmacoeconomics and Outcomes Research. 2021, 21, 43-54.	1.4	22

#	Article	IF	CITATIONS
19	Serum glycated albumin predicts all-cause mortality in dialysis patients with diabetes mellitus: meta-analysis and systematic review of a predictive biomarker. Acta Diabetologica, 2021, 58, 81-91.	2.5	24
20	Application of survival classification and regression tree analysis for identification of subgroups of risk in patients with heart failure and reduced left ventricular ejection fraction. International Journal of Cardiovascular Imaging, 2021, 37, 1853-1861.	1.5	3
21	Effect of Coffee Consumption on Renal Outcome: A Systematic Review and Meta-Analysis of Clinical Studies. , 2021, 31, 5-20.		17
22	A Systematic Review on Bleeding Risk Scores' Accuracy after Percutaneous Coronary Interventions in Acute and Elective Settings. Healthcare (Switzerland), 2021, 9, 148.	2.0	4
23	Role of Klotho in the Development of Essential Hypertension. Hypertension, 2021, 77, 740-750.	2.7	51
24	Molecular Genetic Approach and Evaluation of Cardiovascular Events in Patients with Clinical Familial Hypercholesterolemia Phenotype from Romania. Journal of Clinical Medicine, 2021, 10, 1399.	2.4	3
25	Association between serum osteoprotegerin level and mortality in kidney transplant recipients ―a prospective observational cohort study. Transplant International, 2021, 34, 844-854.	1.6	2
26	The influence of obstructive sleep apnea syndrome on anthropometric parameters at 12Âmonths after laparoscopic sleeve gastrectomy. Scientific Reports, 2021, 11, 5781.	3.3	0
27	A call to optimize haemodialysis vascular access care in healthcare disrupted by COVID-19 pandemic. Journal of Nephrology, 2021, 34, 365-368.	2.0	6
28	Involvement of KL-6 Biomarker in Interstitial Lung Disease Induced by SARS-CoV-2 Infection: A Systematic Review. Applied Sciences (Switzerland), 2021, 11, 3482.	2.5	4
29	Cardionephrology from the point of view of the cardiologist: no more agree to disagree—getting to â€~yes' for every patient. CKJ: Clinical Kidney Journal, 2021, 14, 1995-1999.	2.9	6
30	FC 028COVID-19 RELATED MORTALITYÂIN KIDNEY TRANSPLANT AND DIALYSIS PATIENTS: A COMPARATIVE, PROSPECTIVE REGISTRY BASED STUDY. Nephrology Dialysis Transplantation, 2021, 36, .	0.7	5
31	Computational Models Used to Predict Cardiovascular Complications in Chronic Kidney Disease Patients: A Systematic Review. Medicina (Lithuania), 2021, 57, 538.	2.0	5
32	Mitochondrion-driven nephroprotective mechanisms of novel glucose lowering medications. Mitochondrion, 2021, 58, 72-82.	3.4	13
33	Safety and Efficacy of Minimum- or Zero-Contrast IVUS–Guided Percutaneous Coronary Interventions in Chronic Kidney Disease Patients: A Systematic Review. Journal of Clinical Medicine, 2021, 10, 1996.	2.4	5
34	Coronary artery bypass grafting versus percutaneous coronary intervention in <scp>endâ€stage</scp> kidney disease: A systematic review and <scp>metaâ€analysis</scp> of clinical studies. Hemodialysis International, 2021, 25, 288-299.	0.9	2
35	The Speed of Ingestion of a Sugary Beverage Has an Effect on the Acute Metabolic Response to Fructose. Nutrients, 2021, 13, 1916.	4.1	12
36	<scp>Sodiumâ€glucose</scp> cotransporter 2 inhibitors for diabetes mellitus control after kidney transplantation: Review of the current evidence. Nephrology, 2021, 26, 1007-1017.	1.6	10

#	Article	IF	CITATIONS
37	A randomized multicenter trial on a lung ultrasound–guided treatment strategy in patients on chronic hemodialysis with high cardiovascular risk. Kidney International, 2021, 100, 1325-1333.	5.2	45
38	Measuring Heart Rate Variability in Patients Admitted with ST-Elevation Myocardial Infarction for the Prediction of Subsequent Cardiovascular Events: A Systematic Review. Medicina (Lithuania), 2021, 57, 1021.	2.0	6
39	Substitution of Sugar-Sweetened Beverages for Other Beverages: Can It Be the Next Step Towards Healthy Aging?. Current Nutrition Reports, 2021, 10, 399-412.	4.3	4
40	Clostridioides difficile Infection in Patients with Chronic Kidney Disease: A Systematic Review. BioMed Research International, 2021, 2021, 1-10.	1.9	1
41	Pharmacologic and interventional paradigms of diuretic resistance in congestive heart failure: a narrative review. International Urology and Nephrology, 2021, 53, 1839-1849.	1.4	6
42	Therapeutic implications of shared mechanisms in non-alcoholic fatty liver disease and chronic kidney disease. Journal of Nephrology, 2021, 34, 649-659.	2.0	13
43	Frailty in Older Dialysis Patients. , 2021, , 151-171.		1
44	Influencing Cardiovascular Outcomes through Heart Rate Variability Modulation: A Systematic Review. Diagnostics, 2021, 11, 2198.	2.6	13
45	Halotherapy—An Ancient Natural Ally in the Management of Asthma: A Comprehensive Review. Healthcare (Switzerland), 2021, 9, 1604.	2.0	3
46	Left atrial strain: A novel "biomarker―for chronic kidney disease patients?. Echocardiography, 2021, 38, 2077-2082.	0.9	4
47	The Association between Coffee and Caffeine Consumption and Renal Function: Insight from Individual-Level Data, Mendelian Randomization, and Meta-Analysis. Archives of Medical Science, 2021, ,	0.9	1
48	lmmunogenicity of SARS-CoV-2 mRNA vaccine in dialysis and kidney transplant patients: A systematic review. Tuberkuloz Ve Toraks, 2021, 69, 547-560.	0.4	8
49	Challenging the supremacy of evidence-based medicine through artificial intelligence: the time has come for a change of paradigms. Nephrology Dialysis Transplantation, 2020, 35, 191-194.	0.7	6
50	Protein convertase subtilisin/kexin type 9 biology in nephrotic syndrome: implications for use as therapy. Nephrology Dialysis Transplantation, 2020, 35, 1663-1674.	0.7	13
51	Inflammation is an amplifier of lung congestion by high lv filling pressure in hemodialysis patients: a longitudinal study. Journal of Nephrology, 2020, 33, 583-590.	2.0	4
52	The Effect of Urine pH and Urinary Uric Acid Levels on the Development of Contrast Nephropathy. Kidney and Blood Pressure Research, 2020, 45, 131-141.	2.0	13
53	An update review of intradialytic hypotension: concept, risk factors, clinical implications and management. CKJ: Clinical Kidney Journal, 2020, 13, 981-993.	2.9	89
54	Complications of metabolic acidosis and alkalinizing therapy in chronic kidney disease patients: a clinician-directed organ-specific primer. International Urology and Nephrology, 2020, 52, 2311-2320.	1.4	7

#	Article	IF	CITATIONS
55	Prognostic value of lung ultrasonography and bioimpedance spectroscopy in patients with heart failure and reduced ejection fraction. Archives of Medical Science, 2020, , .	0.9	1
56	Adverse Impact of Desulfovibrio spp. and Beneficial Role of Anaerostipes spp. on Renal Function: Insights from a Mendelian Randomization Analysis. Nutrients, 2020, 12, 2216.	4.1	21
57	Using the SYNTAX score to predict myocardial injury early after on-pump coronary artery bypass surgery: 76 a single-centre experience analysis. Kardiochirurgia I Torakochirurgia Polska, 2020, 17, 76-82.	0.1	2
58	Peculiarities and Consequences of Different Angiographic Patterns of STEMI Patients Receiving Coronary Angiography Only: Data from a Large Primary PCI Registry. Emergency Medicine International, 2020, 2020, 1-7.	0.8	1
59	Sweet dreams: therapeutic insights, targeting imaging and physiologic evidence linking sleep, melatonin and diabetic nephropathy. CKJ: Clinical Kidney Journal, 2020, 13, 522-530.	2.9	6
60	Longer or shorter dual antiplatelet therapy in dialysis patients receiving a coronary drug-eluting stent? A rope game still ongoing. CKJ: Clinical Kidney Journal, 2020, 13, 749-752.	2.9	1
61	Recommendations for the prevention, mitigation and containment of the emerging SARS-CoV-2 (COVID-19) pandemic in haemodialysis centres. Nephrology Dialysis Transplantation, 2020, 35, 737-741.	0.7	215
62	Using Artificial Intelligence Resources in Dialysis and Kidney Transplant Patients: A Literature Review. BioMed Research International, 2020, 2020, 1-14.	1.9	27
63	The Devil Is in theÂDetails When Considering the OACÂEfficacy-Safety Equation in DialysisÂPatients. Journal of the American College of Cardiology, 2020, 76, 349-350.	2.8	1
64	Characteristics of Patients Who Achieve Serum Phosphorus Control on Sucroferric Oxyhydroxide or Sevelamer Carbonate: A post hoc Analysis of a Phase 3 Study. Nephron, 2020, 144, 428-439.	1.8	2
65	Serum osmolarity as a potential predictor for contrast-induced nephropathy following elective coronary angiography. International Urology and Nephrology, 2020, 52, 541-547.	1.4	3
66	Eco-dialysis: fashion or necessity. International Urology and Nephrology, 2020, 52, 519-523.	1.4	9
67	Effect of Uric Acid-Lowering Agents on Cardiovascular Outcome in Patients With Heart Failure: A Systematic Review and Meta-Analysis of Clinical Studies. Angiology, 2020, 71, 315-323.	1.8	22
68	Exploring Current Evidence on the Past, the Present, and the Future of the Heart Team: A Narrative Review. Cardiovascular Therapeutics, 2020, 2020, 1-8.	2.5	7
69	Extracorporeal Membrane Oxygenation in Cardiogenic Shock due to Acute Myocardial Infarction: A Systematic Review. BioMed Research International, 2020, 2020, 1-9.	1.9	14
70	Assessment and Management of Volume Overload Among Patients on Chronic Dialysis. Current Vascular Pharmacology, 2020, 19, 34-40.	1.7	3
71	Relation Between PTH and the Risk of Mortality in CKD. , 2020, , 187-193.		0
72	Can Incidental Vascular Calcifications at Mammography be Used as a Screening Biomarker for Heart and Kidney Disease?. Angiology, 2019, 70, 210-219.	1.8	1

#	Article	IF	CITATIONS
73	Serum phosphate optimal timing and range associated with patients survival in haemodialysis: the COSMOS study. Nephrology Dialysis Transplantation, 2019, 34, 673-681.	0.7	23
74	Evaluation of low-dose glucocorticoid regimen in association with cyclophosphamide in patients with glomerulonephritis. International Urology and Nephrology, 2019, 51, 1805-1813.	1.4	4
75	Nephrology in the Eastern and Central European region: challenges and opportunities. Kidney International, 2019, 96, 287-290.	5.2	15
76	Coexistent papillary thyroid carcinoma diagnosed in surgically treated patients for primary versus secondary hyperparathyroidism: same incidence, different characteristics. BMC Surgery, 2019, 19, 94.	1.3	12
77	Renal hyperfiltration defined by high estimated glomerular filtration rate: A risk factor for cardiovascular disease and mortality. Diabetes, Obesity and Metabolism, 2019, 21, 2368-2383.	4.4	56
78	<p>Invasive pulmonary infection due to Thermoascus crustaceus in a kidney transplant recipient</p> . Infection and Drug Resistance, 2019, Volume 12, 1929-1934.	2.7	3
79	Strategies to Lower In-Hospital Mortality in STEMI Patients with Primary PCI: Analysing Two Years Data from a High-Volume Interventional Centre. Journal of Interventional Cardiology, 2019, 2019, 1-6.	1.2	6
80	A journey from microenvironment to macroenvironment: the role of metaflammation and epigenetic changes in cardiorenal disease. CKJ: Clinical Kidney Journal, 2019, 12, 861-870.	2.9	14
81	Anticoagulation in Concomitant Chronic Kidney Disease and AtrialÂFibrillation. Journal of the American College of Cardiology, 2019, 74, 2204-2215.	2.8	94
82	Antidiuretic Hormone and Serum Osmolarity Physiology and Related Outcomes: What Is Old, What Is New, and What Is Unknown?. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 5406-5420.	3.6	27
83	Cardioprotective apelin effects and the cardiac-renal axis: review of existing science and potential therapeutic applications of synthetic and native regulated apelin. Journal of Human Hypertension, 2019, 33, 429-435.	2.2	14
84	Multiâ€modality cardiac imaging in advanced chronic kidney disease. Echocardiography, 2019, 36, 1372-1380.	0.9	6
85	Association of intracellular lipid accumulation in subcutaneous adipocyte precursors and plasma adipokines in bariatric surgery candidates. Lipids in Health and Disease, 2019, 18, 141.	3.0	7
86	A comprehensive review on apolipoproteins as nontraditional cardiovascular risk factors in end-stage renal disease: current evidence and perspectives. International Urology and Nephrology, 2019, 51, 1173-1189.	1.4	10
87	The role of uric acid in mineral bone disorders in chronic kidney disease. Journal of Nephrology, 2019, 32, 709-717.	2.0	8
88	Religiosity, spirituality and quality of life of dialysis patients: a systematic review. International Urology and Nephrology, 2019, 51, 839-850.	1.4	30
89	Pros and cons of antithrombotic therapy in end-stage kidney disease: a 2019 update. Nephrology Dialysis Transplantation, 2019, 34, 923-933.	0.7	23
90	Novel percutaneous interventional therapies in heart failure with preserved ejection fraction: an integrative review. Heart Failure Reviews, 2019, 24, 793-803.	3.9	11

#	Article	IF	CITATIONS
91	Incremental haemodialysis and residual kidney function: more and more observations but no trials. Nephrology Dialysis Transplantation, 2019, 34, 1806-1811.	0.7	11
92	Novel insights into parathyroid hormone: report of The Parathyroid Day in Chronic Kidney Disease. CKJ: Clinical Kidney Journal, 2019, 12, 269-280.	2.9	29
93	Multilayered Interplay Between Fructose and Salt in Development of Hypertension. Hypertension, 2019, 73, 265-272.	2.7	18
94	Rapid decline of kidney function in diabetic kidney disease is associated with high soluble Klotho levels. Nefrologia, 2019, 39, 250-257.	0.4	12
95	Air pollution and kidney disease: review of current evidence. CKJ: Clinical Kidney Journal, 2019, 12, 19-32.	2.9	78
96	An analysis of the impact of fluid overload and fluid depletion for all-cause and cardiovascular mortality. Nephrology Dialysis Transplantation, 2019, 34, 1385-1393.	0.7	20
97	Should a fistula first policy be revisited in elderly haemodialysis patients?. Nephrology Dialysis Transplantation, 2019, 34, 1636-1643.	0.7	32
98	The predictive value of malnutrition for functional and cognitive status in elderly hemodialysis patients. International Urology and Nephrology, 2019, 51, 155-162.	1.4	25
99	The effect of chronic kidney disease on lipid metabolism. International Urology and Nephrology, 2019, 51, 265-277.	1.4	32
100	Gut microbiota and inflammation in chronic kidney disease and their roles in the development of cardiovascular disease. Hypertension Research, 2019, 42, 123-140.	2.7	72
101	Severe hyponatremia after direct-acting antiviral treatment in a patient with virus C compensated liver cirrhosis and kidney transplant. Journal of Gastrointestinal and Liver Diseases, 2019, 27, 203-204.	0.9	1
102	Hemodialysis in theÂElderly. , 2019, , 147-162.		0
103	Effects of Volume Overload and Current Techniques for the Assessment of Fluid Status in Patients with Renal Disease. Blood Purification, 2018, 46, 34-47.	1.8	60
104	The impact of exercise on physical function, cardiovascular outcomes and quality of life in chronic kidney disease patients: a systematic review. International Urology and Nephrology, 2018, 50, 885-904.	1.4	62
105	Use of Lung Ultrasound for the Assessment of Volume Status in CKD. American Journal of Kidney Diseases, 2018, 71, 412-422.	1.9	48
106	Chronic kidney disease and stroke: more observations but no trials. Nephrology Dialysis Transplantation, 2018, 33, 367-370.	0.7	2
107	Primary Prevention of Stroke in Chronic Kidney Disease Patients: A Scientific Update. Cerebrovascular Diseases, 2018, 45, 33-41.	1.7	4
108	â€~ Some doors are better left closed ': Using LAA occluders as an alternative to warfarin in very high-risk dialysed patients with atrial fibrillation. International Journal of Cardiology, 2018, 262, 43-44.	1.7	0

#	Article	IF	CITATIONS
109	Disorders of Lipid Metabolism in Chronic Kidney Disease. Blood Purification, 2018, 46, 144-152.	1.8	95
110	In Reply to â€~Thoracic Ultrasound Artifacts: Still a Matter of Discussion'. American Journal of Kidney Diseases, 2018, 71, 911.	1.9	7
111	Is Kt/V useful in elderly dialysis patients? Pro and Con arguments. Nephrology Dialysis Transplantation, 2018, 33, 742-750.	0.7	26
112	Modifications in the spectrum of bone mass predictive factors with menopausal status. Endocrine Research, 2018, 43, 176-185.	1.2	7
113	Cardiovascular Effects of Continuous Positive Airway Pressure Treatment in Patients With Obstructive Sleep Apnea: A Meta-Analysis. Angiology, 2018, 69, 195-204.	1.8	11
114	Effect of renin–angiotensin–aldosterone system blockade in adults with diabetes mellitus and advanced chronic kidney disease not on dialysis: a systematic review and meta-analysis. Nephrology Dialysis Transplantation, 2018, 33, 12-22.	0.7	39
115	Magnesium supplementation: A consideration in dialysis patients. Seminars in Dialysis, 2018, 31, 11-14.	1.3	14
116	B-lines score on lung ultrasound as a direct measure of respiratory dysfunction in ICU patients with acute kidney injury. International Urology and Nephrology, 2018, 50, 113-119.	1.4	19
117	Bone and mineral disorders in chronic kidney disease: implications for cardiovascular health and ageing in the general population. Lancet Diabetes and Endocrinology,the, 2018, 6, 319-331.	11.4	102
118	Overhydration, underhydration, and total body sodium: A tricky "ménage a trois―in dialysis patients. Seminars in Dialysis, 2018, 31, 21-25.	1.3	9
119	Prospective Validation of a Screening Biomarker Approach Combining Amino-Terminal Pro-Brain Natriuretic Peptide With Galectin-3 Predicts Death and Cardiovascular Events in Asymptomatic Hemodialysis Patients. Angiology, 2018, 69, 449-455.	1.8	10
120	Iron in kidney and heart failure: from theory to practice. International Urology and Nephrology, 2018, 50, 481-493.	1.4	8
121	Bleeding in advanced CKD patients on antithrombotic medication – A critical appraisal. Pharmacological Research, 2018, 129, 535-543.	7.1	16
122	Acute effects of salt on blood pressure are mediated by serum osmolality. Journal of Clinical Hypertension, 2018, 20, 1447-1454.	2.0	27
123	Arterial stiffness mediates the effect of salt intake on systolic blood pressure. Journal of Clinical Hypertension, 2018, 20, 1587-1594.	2.0	11
124	A Narrative Review on Thrombolytics in Advanced CKD: Is it an Evidence-Based Therapy?. Cardiovascular Drugs and Therapy, 2018, 32, 463-475.	2.6	2
125	Practical issues in clinical scenarios involving CKD patients requiring antithrombotic therapy in light of the 2017 ESC guideline recommendations. BMC Medicine, 2018, 16, 158.	5.5	15
126	Which anticoagulants should be used for stroke prevention in non-valvular atrial fibrillation and severe chronic kidney disease?. Current Opinion in Nephrology and Hypertension, 2018, 27, 420-425.	2.0	9

#	Article	IF	CITATIONS
127	Atrial fibrillation in dialysis patients: is there a place for non-vitamin K antagonist oral anticoagulants?. International Urology and Nephrology, 2018, 50, 1633-1642.	1.4	3
128	Salt Intake and Immunity. Hypertension, 2018, 72, 19-23.	2.7	34
129	Capillary rarefaction from the kidney point of view. CKJ: Clinical Kidney Journal, 2018, 11, 295-301.	2.9	52
130	The Future of IL-1 Targeting in Kidney Disease. Drugs, 2018, 78, 1073-1083.	10.9	18
131	The Effects of Bariatric Surgery on Renal Outcomes: a Systematic Review and Meta-analysis. Obesity Surgery, 2018, 28, 3815-3833.	2.1	39
132	The crosstalk of gut microbiota and chronic kidney disease: role of inflammation, proteinuria, hypertension, and diabetes mellitus. International Urology and Nephrology, 2018, 50, 1453-1466.	1.4	105
133	FP003ANALYSIS OF PROGNOSTIC FACTORS FOR SURVIVAL IN A LARGE COHORT OF ETHYLENE GLYCOL INTOXICATION CASES. Nephrology Dialysis Transplantation, 2018, 33, i50-i51.	0.7	2
134	Blood pressure and kidney update 2016/2017. Archives of Medical Science, 2018, , .	0.9	0
135	Dialysis modality choice in elderly patients with end-stage renal disease: a narrative review of the available evidence: TableÂ1 Nephrology Dialysis Transplantation, 2017, 32, gfv411.	0.7	37
136	Iron-related parameters in dialysis patients treated with sucroferric oxyhydroxide. Nephrology Dialysis Transplantation, 2017, 32, gfw242.	0.7	32
137	Serum Uric Acid and Risk for Acute Kidney Injury Following Contrast. Angiology, 2017, 68, 132-144.	1.8	38
138	Thyroid function and cardiovascular events in chronic kidney disease patients. Journal of Nephrology, 2017, 30, 235-242.	2.0	24
139	Dietary and commercialized fructose: Sweet or sour?. International Urology and Nephrology, 2017, 49, 1611-1620.	1.4	25
140	Colchicine in Renal Medicine: New Virtues of an Ancient Friend. Blood Purification, 2017, 43, 125-135.	1.8	19
141	Clinical Practice Guideline on management of older patients with chronic kidney disease stage 3b or higher (eGFR<45 mL/min/1.73 m2): a summary document from the European Renal Best Practice Group. Nephrology Dialysis Transplantation, 2017, 32, 9-16.	0.7	120
142	Positioning novel biologicals in CKD-mineral and bone disorders. Journal of Nephrology, 2017, 30, 689-699.	2.0	11
143	Considerations on glycaemic control in older and/or frail individuals with diabetes and advanced kidney disease. Nephrology Dialysis Transplantation, 2017, 32, 591-597.	0.7	6
144	The quest for equilibrium: exploring the thin red line between bleeding and ischaemic risks in the management of acute coronary syndromes in chronic kidney disease patients. Nephrology Dialysis Transplantation, 2017, 32, 1967-1976.	0.7	14

#	Article	IF	CITATIONS
145	Vascular Damage in Children With Chronic Kidney Disease. Hypertension, 2017, 69, 791-794.	2.7	3
146	The impact of periodontal disease on physical and psychological domains in long-term hemodialysis patients: a cross-sectional study. International Urology and Nephrology, 2017, 49, 1261-1266.	1.4	7
147	Dry weight assessment by combined ultrasound and bioimpedance monitoring in low cardiovascular risk hemodialysis patients: a randomized controlled trial. International Urology and Nephrology, 2017, 49, 143-153.	1.4	47
148	Coronary risk score for mineral bone disease in chronic non-diabetic hemodialysis patients: results from a prospective pilot study. International Urology and Nephrology, 2017, 49, 689-700.	1.4	1
149	Value of bioimpedance analysis estimated "dry weight―in maintenance dialysis patients: a systematic review and meta-analysis. International Urology and Nephrology, 2017, 49, 2231-2245.	1.4	69
150	Addition of silymarin to renin–angiotensin system blockers in normotensive patients with type 2 diabetes mellitus and proteinuria: a prospective randomized trial. International Urology and Nephrology, 2017, 49, 2195-2204.	1.4	11
151	Secondary Causes: Work-Up and Its Specificities in CKD: Influence of Volume Overload, Excess Sodium Intake and Retention in CKD. , 2017, , 169-182.		0
152	Tubular secretion in chronic kidney disease staging: a new proposal. International Urology and Nephrology, 2017, 49, 2087-2089.	1.4	2
153	Real-World Impact of Cardiovascular Disease and Anemia on Quality of Life and Productivity in Patients with Non-Dialysis-Dependent Chronic Kidney Disease. Advances in Therapy, 2017, 34, 1662-1672.	2.9	40
154	Novel Faces of Fibroblast Growth Factor 23 (FGF23): Iron Deficiency, Inflammation, Insulin Resistance, Left Ventricular Hypertrophy, Proteinuria and Acute Kidney Injury. Calcified Tissue International, 2017, 100, 217-228.	3.1	34
155	Potential novel biomarkers of cardiovascular dysfunction and disease: cardiotrophin-1, adipokines and galectin-3. Archives of Medical Science, 2017, 4, 897-913.	0.9	48
156	Predictive abilities of baseline measurements of fluid overload, assessed by bioimpedance spectroscopy and serum N-terminal pro-B-type natriuretic peptide, for mortality in hemodialysis patients. Archives of Medical Science, 2017, 5, 1121-1129.	0.9	15
157	Impact of surgical parathyroidectomy on chronic kidney disease-mineral and bone disorder (CKD-MBD) – A systematic review and meta-analysis. PLoS ONE, 2017, 12, e0187025.	2.5	46
158	Clinical SYNTAX Score – a good predictor for renal artery stenosis in acute myocardial infarction patients: analysis from the REN-ACS trial. Archives of Medical Science, 2017, 4, 837-844.	0.9	4
159	Correlation Between Recombinant Human Erythropoietin Dose and Inflammatory Status in Dialysed Patients. Revista De Chimie (discontinued), 2017, 68, 354-357.	0.4	1
160	Silymarin in Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Journal of Diabetes Research, 2016, 2016, 1-10.	2.3	66
161	MP596WHAT IS THE BEST METHOD FOR ASSESSING FUNCTIONAL STATUS IN ELDERLY PATIENTS WITH CHRONIC KIDNEY DISEASE?. Nephrology Dialysis Transplantation, 2016, 31, i539-i540.	0.7	0
162	Endostatin in chronic kidney disease: Associations with inflammation, vascular abnormalities, cardiovascular events and survival. European Journal of Internal Medicine, 2016, 33, 81-87.	2.2	25

#	Article	IF	CITATIONS
163	Increased arterial stiffness predicts cognitive impairment in hemodialysis patients. Hemodialysis International, 2016, 20, 463-472.	0.9	15
164	Magnesium-based interventions for normal kidney function and chronic kidney disease. Magnesium Research, 2016, 29, 126-140.	0.5	18
165	Criteria for and Appropriateness of Renal Transplantation in Elderly Patients With End-Stage Renal Disease. Transplantation, 2016, 100, e55-e65.	1.0	63
166	Hypertension as an autoimmune and inflammatory disease. Hypertension Research, 2016, 39, 567-573.	2.7	142
167	Atrial fibrillation in chronic kidney disease. European Journal of Internal Medicine, 2016, 33, 3-13.	2.2	14
168	Hypertension in Chronic Kidney Disease Part 1. Hypertension, 2016, 67, 1093-1101.	2.7	63
169	Hypertension in Chronic Kidney Disease Part 2. Hypertension, 2016, 67, 1102-1110.	2.7	86
170	Efficacy of a remote web-based lung ultrasound training for nephrologists and cardiologists: a LUST trial sub-project. Nephrology Dialysis Transplantation, 2016, 31, 1982-1988.	0.7	60
171	The Agreement between Auscultation and Lung Ultrasound in Hemodialysis Patients: The LUST Study. Clinical Journal of the American Society of Nephrology: CJASN, 2016, 11, 2005-2011.	4.5	124
172	The role of sodium intake in nephrolithiasis: epidemiology, pathogenesis, and future directions. European Journal of Internal Medicine, 2016, 35, 16-19.	2.2	29
173	<scp>SPRINT</scp> : The Study Nephrologists Might Take With a Grain of Salt. Journal of Clinical Hypertension, 2016, 18, 1185-1188.	2.0	5
174	Sclerostin, cardiovascular disease and mortality: a systematic review and meta-analysis. International Urology and Nephrology, 2016, 48, 2029-2042.	1.4	46
175	The Role of Plasma Triglyceride/Highâ€Ðensity Lipoprotein Cholesterol Ratio to Predict New Cardiovascular Events in Essential Hypertensive Patients. Journal of Clinical Hypertension, 2016, 18, 772-777.	2.0	53
176	Brain-kidney cross-talk: Definition and emerging evidence. European Journal of Internal Medicine, 2016, 36, 7-12.	2.2	25
177	Severity of coronary artery disease is an independent risk factor for decline in kidney function. European Journal of Internal Medicine, 2016, 33, 93-97.	2.2	6
178	SP568WHAT IS THE BENEFIT OF DIALYSIS IN FRAIL ELDERLY PATIENTS?. Nephrology Dialysis Transplantation, 2016, 31, i282-i282.	0.7	0
179	Novel Masters of Erythropoiesis: Hypoxia Inducible Factors and Recent Advances in Anemia of Renal Disease. Blood Purification, 2016, 42, 160-167.	1.8	16
180	Wnt/Sclerostin and the Relation with Vitamin D in Chronic Kidney Disease. , 2016, , 207-216.		0

#	Article	IF	CITATIONS
181	Clinical Practice Guideline on management of older patients with chronic kidney disease stage 3b or higher (eGFR <45 mL/min/1.73 m ²). Nephrology Dialysis Transplantation, 2016, 31, ii1-ii66.	0.7	87
182	Bioimpedance analysis versus lung ultrasonography for optimal risk prediction in hemodialysis patients. International Journal of Cardiovascular Imaging, 2016, 32, 263-270.	1.5	42
183	Clinical Validation of a Peritoneal Dialysis Prescription Model in the PatientOnLine Software. Artificial Organs, 2016, 40, 144-152.	1.9	4
184	New molecular insights in diabetic nephropathy. International Urology and Nephrology, 2016, 48, 373-387.	1.4	9
185	Focus on renal congestion in heart failure. CKJ: Clinical Kidney Journal, 2016, 9, 39-47.	2.9	77
186	PTH and/or Bone Histology: Are We Still Waiting for a Verdict From the CKD-MBD Grand Jury?. American Journal of Kidney Diseases, 2016, 67, 535-538.	1.9	11
187	Morning Blood Pressure Surge as a Predictor of Development of Chronic Kidney Disease. Journal of Clinical Hypertension, 2016, 18, 444-448.	2.0	27
188	Priority topics for European multidisciplinary guidelines on the management of chronic kidney disease in older adults. International Urology and Nephrology, 2016, 48, 859-869.	1.4	12
189	Relevance of uric acid and asymmetric dimethylarginine for modeling cardiovascular risk prediction in chronic kidney disease patients. International Urology and Nephrology, 2016, 48, 1129-1136.	1.4	20
190	Osteoprotegerin in Chronic Kidney Disease: Associations with Vascular Damage and Cardiovascular Events. Calcified Tissue International, 2016, 99, 121-130.	3.1	22
191	Predictive Value for Galectin 3 and Cardiotrophin 1 in Hemodialysis Patients. Angiology, 2016, 67, 854-859.	1.8	24
192	Clinical imaging of vascular disease in chronic kidney disease. International Urology and Nephrology, 2016, 48, 827-837.	1.4	11
193	Recommendations for the use of tolvaptan in autosomal dominant polycystic kidney disease: a position statement on behalf of the ERA-EDTA Working Groups on Inherited Kidney Disorders and European Renal Best Practice. Nephrology Dialysis Transplantation, 2016, 31, 337-348.	0.7	206
194	The impact of basal insulin analogues on glucose variability in patients with type 2 diabetes undergoing renal replacement therapy for end-stage renal disease. International Urology and Nephrology, 2016, 48, 265-270.	1.4	7
195	Does pre-emptive transplantation versus post start of dialysis transplantation with a kidney from a living donor improve outcomes after transplantation? A systematic literature review and position statement by the Descartes Working Group and ERBP. Nephrology Dialysis Transplantation, 2016, 31, 691-697.	0.7	62
196	Clinical value of ambulatory blood pressure: Is it time to recommend for all patients with hypertension?. Clinical and Experimental Nephrology, 2016, 20, 14-22.	1.6	15
197	The Survival of Roma Minority Patients on Chronic Hemodialysis Therapy - A Romanian Multicenter Survey. PLoS ONE, 2016, 11, e0155271.	2.5	6
198	Lipids, blood pressure and kidney update 2015. Lipids in Health and Disease, 2015, 14, 167.	3.0	49

#	Article	IF	CITATIONS
199	Haemodiafiltration, haemofiltration and haemodialysis for end-stage kidney disease. The Cochrane Library, 2015, 2015, CD006258.	2.8	61
200	Serum osteoprotegerin is associated with pulse pressure in kidney transplant recipients. Scientific Reports, 2015, 5, 14518.	3.3	8
201	Overhydration, Cardiac Function and Survival in Hemodialysis Patients. PLoS ONE, 2015, 10, e0135691.	2.5	87
202	FP723PULMONARY CONGESTION AND MORTALITY RISK PREDICTION IN HAEMODIALYSIS PATIENTS. Nephrology Dialysis Transplantation, 2015, 30, iii318-iii318.	0.7	0
203	Renalase: Another puzzle piece between hypertension and simple renal cysts?. International Urology and Nephrology, 2015, 47, 1181-1186.	1.4	5
204	From Profusion to Confusion: The Saga of Managing Hypertension in Chronic Kidney Disease!. Journal of Clinical Hypertension, 2015, 17, 421-427.	2.0	4
205	Atherosclerotic Renal Artery Stenosis Prevalence and Correlations in Acute Myocardial Infarction Patients Undergoing Primary Percutaneous Coronary Interventions: Data From Nonrandomized Singleâ€Center Study (RENâ€ACS)—A Single Center, Prospective, Observational Study. Journal of the American Heart Association, 2015, 4, e002379.	3.7	17
206	Why creating standardized core outcome sets for chronic kidney disease will improve clinical practice. Nephrology Dialysis Transplantation, 2015, 32, gfv365.	0.7	18
207	Serum neutrophil gelatinase-associated lipocalin is associated with cardiovascular events in patients with chronic kidney disease. International Urology and Nephrology, 2015, 47, 1993-2001.	1.4	10
208	Treatment Failure of Active Vitamin D Therapy in Chronic Kidney Disease: Predictive Factors. American Journal of Nephrology, 2015, 42, 228-236.	3.1	6
209	Hepatitis B and C Virus Infection in the Hemodialysis Population from Three Romanian Regions. Nephron, 2015, 129, 202-208.	1.8	13
210	Pro: Cardiovascular calcifications are clinically relevant. Nephrology Dialysis Transplantation, 2015, 30, 345-351.	0.7	53
211	Vasopressin receptor antagonists for the treatment of heart failure: a systematic review and meta-analysis of randomized controlled trials. International Urology and Nephrology, 2015, 47, 335-344.	1.4	8
212	New insights into the effect of haemodiafiltration on mortality: the Romanian experience. Nephrology Dialysis Transplantation, 2015, 30, 294-301.	0.7	32
213	Tissue advanced glycation end products (AGEs), measured by skin autofluorescence, predict mortality in peritoneal dialysis. International Urology and Nephrology, 2015, 47, 563-569.	1.4	31
214	Risk-based individualisation of target haemoglobin in haemodialysis patients with renal anaemia in the post-TREAT era: theoretical attitudes versus actual practice patterns (MONITOR-CKD5 study). International Urology and Nephrology, 2015, 47, 837-845.	1.4	3
215	Improvement of mineral and bone metabolism markers is associated with better survival in haemodialysis patients: the COSMOS study. Nephrology Dialysis Transplantation, 2015, 30, 1542-1551.	0.7	140
216	Volume Overload in CKD: Pathophysiology, Assessment Techniques, Consequences and Treatment. , 2015, , 119-144.		1

#	Article	IF	CITATIONS
217	Associations of Fibroblast Growth Factor 23 and Fetuin-A with Coronary Plaque Burden and Plaque Composition in Young Adults. Journal of Investigative Medicine, 2015, 63, 613-619.	1.6	5
218	Lipids, blood pressure and kidney update 2014. Pharmacological Research, 2015, 95-96, 111-125.	7.1	77
219	Persistence of Cardiovascular Risk Factors in Women with Previous Preeclampsia: A Long-term Follow-up Study. Journal of Investigative Medicine, 2015, 63, 641-645.	1.6	48
220	Should patients with CKD stage 5D and biochemical evidence of secondary hyperparathyroidism be prescribed calcimimetic therapy? An ERA-EDTA position statement. Nephrology Dialysis Transplantation, 2015, 30, 698-700.	0.7	23
221	Opponent's comments. Nephrology Dialysis Transplantation, 2015, 30, 357-357.	0.7	6
222	Hyperuricemia is associated with progression of IgA nephropathy. International Urology and Nephrology, 2015, 47, 673-678.	1.4	26
223	Pro and con arguments in using alternative dialysis regimens in the frail and elderly patients. International Urology and Nephrology, 2015, 47, 1809-1816.	1.4	8
224	Phosphodiesterase type 5 inhibitors and kidney disease. International Urology and Nephrology, 2015, 47, 1521-1528.	1.4	34
225	Prognostic significance of 25â€hydroxivitamin <scp>D</scp> entirely explained by a higher comorbidity burden: Experience from a <scp>S</scp> outhâ€ <scp>E</scp> astern <scp>E</scp> uropean <scp>D</scp> ialysis <scp>C</scp> ohort. Hemodialysis International, 2015, 19, 249-255.	0.9	2
226	The double challenge of resistant hypertension and chronic kidney disease. Lancet, The, 2015, 386, 1588-1598.	13.7	147
227	Association of Serum Uric Acid Level With Blood Pressure Variability in Newly Diagnosed Essential Hypertension. Journal of Clinical Hypertension, 2015, 17, 929-935.	2.0	26
228	FP397POST HOC ANALYSIS OF IRON INDICES IN DIALYSIS PATIENTS WITH LOWER VS HIGHER BASELINE FERRITIN IN A PHASE 3 STUDY OF SUCROFERRIC OXYHYDROXIDE. Nephrology Dialysis Transplantation, 2015, 30, iii202-iii202.	0.7	0
229	State-of-the-art biosimilar erythropoietins in the management of renal anemia: lessons learned from Europe and implications for US nephrologists. International Urology and Nephrology, 2015, 47, 1529-1539.	1.4	11
230	Electrocardiogram abnormalities and heart rate variability in predicting mortality and cardiovascular events among hemodialyzed patients. International Urology and Nephrology, 2015, 47, 1703-1708.	1.4	19
231	Pulse Wave Velocity Ratio. Hypertension, 2015, 65, 289-290.	2.7	48
232	Heart Failure in Patients with Chronic Kidney Disease: A Systematic Integrative Review. BioMed Research International, 2014, 2014, 1-21.	1.9	107
233	Assessment of arterial stiffness for clinical and epidemiological studies: methodological considerations for validation and entry into the European Renal and Cardiovascular Medicine registry. Nephrology Dialysis Transplantation, 2014, 29, 232-239.	0.7	81
234	Serum Sclerostin and Adverse Outcomes in Nondialyzed Chronic Kidney Disease Patients. Journal of Clinical Endocrinology and Metabolism, 2014, 99, E1854-E1861.	3.6	99

#	Article	IF	CITATIONS
235	The Relationship between IL-10 Levels and Cardiovascular Events in Patients with CKD. Clinical Journal of the American Society of Nephrology: CJASN, 2014, 9, 1207-1216.	4.5	54
236	An Update on Coronary Artery Disease and Chronic Kidney Disease. International Journal of Nephrology, 2014, 2014, 1-9.	1.3	59
237	Plasma endocan levels associate with inflammation, vascular abnormalities, cardiovascular events, and survival in chronic kidney disease. Kidney International, 2014, 86, 1213-1220.	5.2	123
238	Effects of Allopurinol on Endothelial Dysfunction: A Meta-Analysis. American Journal of Nephrology, 2014, 39, 348-356.	3.1	42
239	Introduction: Mineral Bone Disorder Is a Key Player in Chronic Kidney Disease. Seminars in Nephrology, 2014, 34, 577.	1.6	0
240	Obstructive sleep apnea syndrome and chronic kidney disease: a new cardiorenal risk factor. Clinical and Experimental Hypertension, 2014, 36, 211-216.	1.3	31
241	What Do We Know and Do Not Know About Vitamin D?: A Causal Association Between Vitamin D Receptor Genetic Polymorphism and Hypertension. Journal of Clinical Hypertension, 2014, 16, 627-628.	2.0	6
242	Endocan: A New Molecule Playing a Role in the Development of Hypertension and Chronic Kidney Disease?. Journal of Clinical Hypertension, 2014, 16, 914-916.	2.0	33
243	Relationship Between Elevated Morning Blood Pressure Surge, Uric Acid, and Cardiovascular Outcomes in Hypertensive Patients. Journal of Clinical Hypertension, 2014, 16, 530-535.	2.0	34
244	Uric Acid Level and Erectile Dysfunction in Patients with Coronary Artery Disease. Journal of Sexual Medicine, 2014, 11, 165-172.	0.6	23
245	Oral phosphate binders in CKD – is calcium the (only) answer?. Clinical Nephrology, 2014, 81, 389-395.	0.7	6
246	Superior Predictive Value for NTproBNP Compared with High Sensitivity cTnT in Dialysis Patients: A Pilot Prospective Observational Study. Kidney and Blood Pressure Research, 2014, 39, 636-647.	2.0	19
247	Convective Versus Diffusive Dialysis Therapies for Chronic Kidney Failure: An Updated Systematic Review of Randomized Controlled Trials. American Journal of Kidney Diseases, 2014, 63, 954-967.	1.9	113
248	Lipid, blood pressure and kidney update 2013. International Urology and Nephrology, 2014, 46, 947-961.	1.4	60
249	Procalcitonin: diagnostic value in systemic infections in chronic kidney disease or renal transplant patients. International Urology and Nephrology, 2014, 46, 461-468.	1.4	25
250	Outcomes of dialytic modalities in a large incident registry cohort from Eastern Europe: the Romanian Renal Registry. International Urology and Nephrology, 2014, 46, 443-451.	1.4	20
251	Clinical Evidence on Hemodiafiltration: A Systematic Review and a Metaâ€analysis. Seminars in Dialysis, 2014, 27, 119-127.	1.3	117
252	Vascular calcification in chronic kidney disease: are biomarkers useful for probing the pathobiology and the health risks of this process in the clinical scenario?. Nephrology Dialysis Transplantation, 2014, 29, 1275-1284.	0.7	50

#	Article	IF	CITATIONS
253	Renal Artery Stenting in Patients With Uncontrolled Hypertension: Should We? And to Whom?. Journal of Clinical Hypertension, 2014, 16, 479-481.	2.0	1
254	Protein-energy wasting, as well as overweight and obesity, is a long-term risk factor for mortality in chronic hemodialysis patients. International Urology and Nephrology, 2014, 46, 615-621.	1.4	35
255	Monocyte count/HDL cholesterol ratio and cardiovascular events in patients with chronic kidney disease. International Urology and Nephrology, 2014, 46, 1619-1625.	1.4	196
256	Epidemiology, contributors to, and clinical trials of mortality risk in chronic kidney failure. Lancet, The, 2014, 383, 1831-1843.	13.7	341
257	Routine Bioimpedance-Derived Volume Assessment for All Hypertensives: A New Paradigm. American Journal of Nephrology, 2014, 40, 434-440.	3.1	9
258	Erythropoiesis-Stimulating Agents (ESA) for Preventing the Progression of Chronic Kidney Disease: A Meta-Analysis of 19 Studies. American Journal of Nephrology, 2014, 40, 263-279.	3.1	27
259	Establishing links between alcohol intake, cognitive functions and type 2 diabetes. Archives of Biological Sciences, 2014, 66, 811-817.	0.5	0
260	Changes in the histological spectrum of glomerular diseases in the past 16 years in the North-Eastern region of Romania. BMC Nephrology, 2013, 14, 148.	1.8	13
261	Soluble TWEAK independently predicts atherosclerosis in renal transplant patients. BMC Nephrology, 2013, 14, 144.	1.8	24
262	Serum gamma-glutamyltransferase levels are inversely related to endothelial function in chronic kidney disease. International Urology and Nephrology, 2013, 45, 1071-1078.	1.4	18
263	A pharmacoepidemiological study of the multi-level determinants, predictors, and clinical outcomes of biosimilar epoetin alfa for renal anaemia in haemodialysis patients: background and methodology of the MONITOR-CKD5 study. Internal and Emergency Medicine, 2013, 8, 389-399.	2.0	9
264	Hyperphosphatemia in patients with ESRD: assessing the current evidence linking outcomes with treatment adherence. BMC Nephrology, 2013, 14, 153.	1.8	64
265	Editors message. International Urology and Nephrology, 2013, 45, 1537-1537.	1.4	0
266	Mean corpuscular volume is associated with endothelial dysfunction and predicts composite cardiovascular events in patients with chronic kidney disease. Nephrology, 2013, 18, 728-735.	1.6	46
267	Kidney Disease: Improving Global Outcomes guidelines on anaemia management in chronic kidney disease: a European Renal Best Practice position statement. Nephrology Dialysis Transplantation, 2013, 28, 1346-1359.	0.7	628
268	Serum calcitonin and endothelial dysfunction in chronic kidney disease: a novel risk factor?. International Urology and Nephrology, 2013, 45, 151-156.	1.4	2
269	Pulmonary Hypertension in CKD. American Journal of Kidney Diseases, 2013, 61, 612-622.	1.9	119
270	Novel techniques and innovation in blood purification: a clinical update from Kidney Disease: Improving Global Outcomes. Kidney International, 2013, 83, 359-371.	5.2	28

#	Article	IF	CITATIONS
271	Randomized Clinical Trial of the Iron-Based Phosphate Binder PA21 in Hemodialysis Patients. Clinical Journal of the American Society of Nephrology: CJASN, 2013, 8, 280-289.	4.5	75
272	Electrocardiographic P-wave characteristics in patients with end-stage renal disease: P-index and interatrial block. International Urology and Nephrology, 2013, 45, 511-517.	1.4	11
273	Low serum pancreatic enzyme levels predict mortality and are associated with malnutrition–inflammation–atherosclerosis syndrome in patients with chronic kidney disease. International Urology and Nephrology, 2013, 45, 477-484.	1.4	11
274	COSMOS: the dialysis scenario of CKD–MBD in Europe. Nephrology Dialysis Transplantation, 2013, 28, 1922-1935.	0.7	79
275	A multicentric, international matched pair analysis of body composition in peritoneal dialysis versus haemodialysis patients. Nephrology Dialysis Transplantation, 2013, 28, 2620-2628.	0.7	61
276	The use of echocardiography in observational clinical trials: the EURECA-m registry. Nephrology Dialysis Transplantation, 2013, 28, 19-23.	0.7	15
277	Global differences in dialysis modality mix: the role of patient characteristics, macroeconomics and renal service indicators. Nephrology Dialysis Transplantation, 2013, 28, 1264-1275.	0.7	35
278	Predicting mortality in haemodialysis patients: a comparison between lung ultrasonography, bioimpedance data and echocardiography parameters. Nephrology Dialysis Transplantation, 2013, 28, 2851-2859.	0.7	94
279	Dialysis-induced segmental wall motion abnormalities, post-dialysis fatigue and cardiovascular mortality: the new Bermuda triangle?. Nephrology Dialysis Transplantation, 2013, 28, 2404-2406.	0.7	4
280	A comparison of calcium acetate/magnesium carbonate and sevelamer-hydrochloride effects on fibroblast growth factor-23 and bone markers: post hoc evaluation from a controlled, randomized study. Nephrology Dialysis Transplantation, 2013, 28, 2383-2392.	0.7	58
281	Dialysis fata morgana: can we finally successfully tackle intradialytic hypotension with plasma sodium biofeedback systems?. Nephrology Dialysis Transplantation, 2013, 28, 250-253.	0.7	2
282	Use of phosphate-binding agents is associated with a lower risk of mortality. Kidney International, 2013, 84, 998-1008.	5.2	136
283	Cinacalcet in Patients with Chronic Kidney Disease: A Cumulative Meta-Analysis of Randomized Controlled Trials. PLoS Medicine, 2013, 10, e1001436.	8.4	117
284	Epic battles in the phosphate-binder wars—the last episode?. Nature Reviews Nephrology, 2013, 9, 497-498.	9.6	0
285	Influence of Body Mass Index on the Association of Weight Changes with Mortality in Hemodialysis Patients. Clinical Journal of the American Society of Nephrology: CJASN, 2013, 8, 1725-1733.	4.5	49
286	Time to Improve Fluid Management in Hemodialysis. Clinical Journal of the American Society of Nephrology: CJASN, 2013, 8, 1474-1475.	4.5	15
287	Efficacy of cinacalcet with low-dose vitamin D in incident haemodialysis subjects with secondary hyperparathyroidism. Nephrology Dialysis Transplantation, 2013, 28, 1241-1254.	0.7	36
288	A systematic review regarding the association of illness perception and survival among end-stage renal disease patients. Nephrology Dialysis Transplantation, 2013, 28, 2407-2414.	0.7	36

#	Article	IF	CITATIONS
289	Magnesium-based interventions for people with chronic kidney disease. The Cochrane Library, 2013, , .	2.8	Ο
290	A longitudinal study on illness perceptions in hemodialysis patients: changes over time. Archives of Medical Science, 2013, 5, 831-836.	0.9	26
291	Hormones and Arterial Stiffness in Patients with Chronic Kidney Disease. Journal of Atherosclerosis and Thrombosis, 2013, 20, 698-707.	2.0	9
292	Uraemic toxins versus volume and water as the major factor that matters with dialysis. Nephrology Dialysis Transplantation, 2012, 27, 58-62.	0.7	28
293	Exploring the Association between Macroeconomic Indicators and Dialysis Mortality. Clinical Journal of the American Society of Nephrology: CJASN, 2012, 7, 1655-1663.	4.5	29
294	Serum Vitamin D Levels are Independently Associated with Severity of Coronary Artery Disease. Journal of Investigative Medicine, 2012, 60, 869-873.	1.6	54
295	Vascular Access Type, Health-Related Quality of Life, and Depression in Hemodialysis Patients: A Preliminary Report. Journal of Vascular Access, 2012, 13, 215-220.	0.9	21
296	Pregabalin versus gabapentin in the treatment of neuropathic pruritus in maintenance haemodialysis patients: A prospective, crossover study. Nephrology, 2012, 17, 710-717.	1.6	80
297	Hantavirus infection—Hemorrhagic fever with renal syndrome: the first case series reported in Romania and review of the literature. International Urology and Nephrology, 2012, 44, 1185-1191.	1.4	7
298	Association of serum calcitonin with coronary artery disease in individuals with and without chronic kidney disease. International Urology and Nephrology, 2012, 44, 1169-1175.	1.4	9
299	Evaluation of advanced glycation end products accumulation, using skin autofluorescence, in CKD and dialysis patients. International Urology and Nephrology, 2012, 44, 1441-1449.	1.4	23
300	A European Renal Best Practice (ERBP) position statement on the Kidney Disease Improving Global Outcomes (KDIGO) Clinical Practice Guidelines on Acute Kidney Injury: Part 1: definitions, conservative management and contrast-induced nephropathy. Nephrology Dialysis Transplantation, 2012, 27, 4263-4272.	0.7	460
301	Medical and Surgical Management (Including Diet). Clinical Reviews in Bone and Mineral Metabolism, 2012, 10, 174-183.	0.8	2
302	Clinical usefulness of novel prognostic biomarkers in patients on hemodialysis. Nature Reviews Nephrology, 2012, 8, 141-150.	9.6	44
303	Relationship between Serum Magnesium Levels and Cardiovascular Events in Chronic Kidney Disease Patients. American Journal of Nephrology, 2012, 36, 228-237.	3.1	103
304	Monocyte subpopulations and cardiovascular risk in chronic kidney disease. Nature Reviews Nephrology, 2012, 8, 362-369.	9.6	143
305	Randomized trial of bioelectrical impedance analysis versus clinical criteria for guiding ultrafiltration in hemodialysis patients: effects on blood pressure, hydration status, and arterial stiffness. International Urology and Nephrology, 2012, 44, 583-591.	1.4	60
306	Obstructive sleep apnea syndrome is related to the progression of chronic kidney disease. International Urology and Nephrology, 2012, 44, 535-539.	1.4	57

#	Article	IF	CITATIONS
307	Changes in arterial stiffness following dialysis in relation to overhydration and to endothelial function. International Urology and Nephrology, 2012, 44, 897-905.	1.4	18
308	Ambulatory blood pressure monitoring: from old concepts to novel insights. International Urology and Nephrology, 2012, 44, 173-182.	1.4	21
309	The prevalence of chronic kidney disease in the general population in Romania: a study on 60,000 persons. International Urology and Nephrology, 2012, 44, 213-220.	1.4	36
310	Renal Anemia of Inflammation: The Name Is Self-Explanatory. Blood Purification, 2011, 32, 220-225.	1.8	62
311	Uric Acid as a Cardiometabolic Risk Factor: To Be or Not to Be. Contributions To Nephrology, 2011, 171, 62-67.	1.1	21
312	Elevated plasma asymmetric dimethylarginine level in acute myocardial infarction patients as a predictor of poor prognosis and angiographic impaired reperfusion. Atherosclerosis, 2011, 219, 304-310.	0.8	26
313	Elevated Serum Uric Acid Predicts Angiographic Impaired Reperfusion and 1-Year Mortality in ST-Segment Elevation Myocardial Infarction Patients Undergoing Percutaneous Coronary Intervention. Journal of Investigative Medicine, 2011, 59, 931-937.	1.6	31
314	Regression of left ventricular hypertrophy in hemodialyzed patients is possible: a follow-up study. International Urology and Nephrology, 2011, 43, 1161-1169.	1.4	4
315	Bone morphogenic protein-7 serum level decreases significantly in patients with contrast-induced nephropathy. International Urology and Nephrology, 2011, 43, 807-812.	1.4	5
316	Allopurinol, uric acid, and oxidative stress in cardiorenal disease. International Urology and Nephrology, 2011, 43, 441-449.	1.4	45
317	Global variation in renal replacement therapy for end-stage renal disease. Nephrology Dialysis Transplantation, 2011, 26, 2604-2610.	0.7	97
318	The dysfunctional endothelium in CKD and in cardiovascular disease: mapping the origin(s) of cardiovascular problems in CKD and of kidney disease in cardiovascular conditions for a research agenda. Kidney International Supplements, 2011, 1, 6-9.	14.2	57
319	The lingering dilemma of arterial pressure in CKD: what do we know, where do we go?. Kidney International Supplements, 2011, 1, 17-20.	14.2	9
320	A Randomized Study of Allopurinol on Endothelial Function and Estimated Glomular Filtration Rate in Asymptomatic Hyperuricemic Subjects with Normal Renal Function. Clinical Journal of the American Society of Nephrology: CJASN, 2011, 6, 1887-1894.	4.5	221
321	Prevalence and Management of Anaemia in Renal Transplant Recipients: Data from Ten European Centres. Nephron Clinical Practice, 2011, 117, c127-c134.	2.3	37
322	Sudden Cardiac Death in Patients with Chronic Kidney Disease: Prevention Is the sine qua non. Kidney and Blood Pressure Research, 2011, 34, 269-276.	2.0	12
323	Serum Uric Acid Level and Endothelial Dysfunction in Patients with Nondiabetic Chronic Kidney Disease. American Journal of Nephrology, 2011, 33, 298-304.	3.1	87
324	Uric Acid and Pentraxin-3 Levels Are Independently Associated with Coronary Artery Disease Risk in Patients with Stage 2 and 3 Kidney Disease. American Journal of Nephrology, 2011, 33, 325-331.	3.1	44

#	Article	IF	CITATIONS
325	Relationship between Uric Acid and Subtle Cognitive Dysfunction in Chronic Kidney Disease. American Journal of Nephrology, 2011, 34, 49-54.	3.1	47
326	Vitamin D Receptor Activation: Clinical Outcomes. Contributions To Nephrology, 2011, 171, 166-171.	1.1	3
327	Microvascular disease and its role in the brain and cardiovascular system: a potential role for uric acid as a cardiorenal toxin. Nephrology Dialysis Transplantation, 2011, 26, 430-437.	0.7	66
328	Major pathways of the reno–cardiovascular link: the sympathetic and renin–angiotensin systems. Kidney International Supplements, 2011, 1, 13-16.	14.2	11
329	The complexity of the cardio–renal link: taxonomy, syndromes, and diseases. Kidney International Supplements, 2011, 1, 2-5.	14.2	24
330	Arterial aging and arterial disease: interplay between central hemodynamics, cardiac work, and organ flow—implications for CKD and cardiovascular disease. Kidney International Supplements, 2011, 1, 10-12.	14.2	44
331	Cardiovascular and non-cardiovascular mortality in dialysis patients: where is the link?. Kidney International Supplements, 2011, 1, 21-23.	14.2	37
332	What would we like to know, and what do we not know about fibroblast growth factor 23. Journal of Nephrology, 2011, 24, 696-706.	2.0	13
333	Modulation of the immune response to HBV vaccination by hemodialysis membranes. International Urology and Nephrology, 2010, 42, 1069-1075.	1.4	7
334	Arterial stiffness in dialysis patients: where are we now?. International Urology and Nephrology, 2010, 42, 741-752.	1.4	51
335	The relationship between chronic volume overload and elevated blood pressure in hemodialysis patients: use of bioimpedance provides a different perspective from echocardiography and biomarker methodologies. International Urology and Nephrology, 2010, 42, 789-797.	1.4	56
336	Endorsement of the Kidney Disease Improving Global Outcomes (KDIGO) Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) Guidelines: a European Renal Best Practice (ERBP) commentary statement. Nephrology Dialysis Transplantation, 2010, 25, 3823-3831.	0.7	85
337	What to Measure at Dialysis Initiation for Reliable Prediction of Cardiovascular Outcomes: Just Look at CRP and Pulse Pressure. Peritoneal Dialysis International, 2010, 30, 280-283.	2.3	1
338	Associations between Serum Leptin Level and Bone Turnover in Kidney Transplant Recipients. Clinical Journal of the American Society of Nephrology: CJASN, 2010, 5, 2297-2304.	4.5	28
339	Diagnosis of Tuberculosis in Dialysis Patients. Clinical Journal of the American Society of Nephrology: CJASN, 2010, 5, 1114-1122.	4.5	70
340	Fibroblast Growth Factor 23 and Fetuin A are Independent Predictors for the Coronary Artery Disease Extent in Mild Chronic Kidney Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2010, 5, 1780-1786.	4.5	78
341	Nebivolol Improves Renal Function in Patients Who Underwent Angioplasty due to Renal Artery Stenosis: A Pilot Study. Nephron Clinical Practice, 2010, 114, c213-c217.	2.3	24
342	The Effects of Vitamin D Therapy on Left Ventricular Structure and Function – Are These the Underlying Explanations for Improved CKD Patient Survival?. Nephron Clinical Practice, 2010, 116, c187-c195.	2.3	36

#	Article	IF	CITATIONS
343	Evaluation of peritoneal membrane characteristics: clinical advice for prescription management by the ERBP working group. Nephrology Dialysis Transplantation, 2010, 25, 2052-2062.	0.7	85
344	Target haemoglobin to aim for with erythropoiesis-stimulating agents: a position statement by ERBP following publication of the Trial to Reduce Cardiovascular Events with Aranesp(R) Therapy (TREAT) Study. Nephrology Dialysis Transplantation, 2010, 25, 2846-2850.	0.7	137
345	The EVEREST study: an international collaboration. CKJ: Clinical Kidney Journal, 2010, 3, 28-36.	2.9	10
346	Sudden Death in Hemodialysis: An Update. Blood Purification, 2010, 30, 135-145.	1.8	48
347	Bone morphogenic protein-7: a new prognostic marker for acute kidney injury?. CKJ: Clinical Kidney Journal, 2010, 3, 106-107.	2.9	1
348	Educating end-stage renal disease patients on dialysis modality selection: clinical advice from the European Renal Best Practice (ERBP) Advisory Board. Nephrology Dialysis Transplantation, 2010, 25, 1757-1759.	0.7	88
349	The safety and efficacy of intravenous ferric carboxymaltose in anaemic patients undergoing haemodialysis: a multi-centre, open-label, clinical study. Nephrology Dialysis Transplantation, 2010, 25, 2722-2730.	0.7	63
350	Kidney and braina renal perspective of 'Les Liaisons Dangereuses'. Nephrology Dialysis Transplantation, 2010, 25, 1370-1373.	0.7	18
351	Time to Reconsider Evidence for Anaemia Treatment (TREAT) = Essential Safety Arguments (ESA). Nephrology Dialysis Transplantation, 2010, 25, 1734-1737.	0.7	16
352	Vascular calcification in chronic kidney disease. Clinical Science, 2010, 119, 111-121.	4.3	88
353	Educating end-stage renal disease patients on dialysis modality selection. CKJ: Clinical Kidney Journal, 2010, 3, 225-233.	2.9	24
354	Uric Acid in Hypertension and Renal Disease: The Chicken or the Egg. Blood Purification, 2010, 30, 288-295.	1.8	57
355	Erythropoiesis Stimulatory Agent- Resistant Anemia in Dialysis Patients: Review of Causes and Management. Blood Purification, 2010, 29, 1-12.	1.8	93
356	Methods and potential biomarkers for the evaluation of endothelial dysfunction in chronic kidney disease: A critical approach. Journal of the American Society of Hypertension, 2010, 4, 116-127.	2.3	38
357	Magnesium in Chronic Kidney Disease: Challenges and Opportunities. Blood Purification, 2010, 29, 280-292.	1.8	83
358	Promoting scientific collaboration and education in cardiovascular-renal medicine: EURECAM: An ERA-EDTA-based working group. CKJ: Clinical Kidney Journal, 2009, 2, 522-525.	2.9	1
359	Phosphate – The Silent Stealthy Cardiorenal Culprit in All Stages of Chronic Kidney Disease. Blood Purification, 2009, 27, 220-230.	1.8	73
360	Blood pressure control in CKD stage 5D patients-are we more or less certain what to do in 2009?. Nephrology Dialysis Transplantation, 2009, 24, 3597-3601.	0.7	10

#	Article	IF	CITATIONS
361	The future of European Nephrology 'Guidelines'a declaration of intent by European Renal Best Practice (ERBP). CKJ: Clinical Kidney Journal, 2009, 2, 213-221.	2.9	7
362	Nutritional status evaluation and survival in haemodialysis patients in one centre from Romania. Nephrology Dialysis Transplantation, 2009, 24, 2536-2540.	0.7	70
363	The Role of the Renin-Angiotensin-Aldosterone System in Renal Artery Stenosis, Renovascular Hypertension, and Ischemic Nephropathy: Diagnostic Implications. Progress in Cardiovascular Diseases, 2009, 52, 204-208.	3.1	29
364	Systematic Review of the Evidence Underlying the Association Between Mineral Metabolism Disturbances and Risk of Fracture and Need for Parathyroidectomy in CKD. American Journal of Kidney Diseases, 2009, 53, 1002-1013.	1.9	34
365	Proâ€Hepcidin Levels in Peritoneal Dialysis and Hemodialysis Patients. Dialysis and Transplantation, 2009, 38, 203-209.	0.2	3
366	Direct renin inhibitors: ONTARGET for success?. International Urology and Nephrology, 2009, 41, 341-355.	1.4	1
367	Sodium bicarbonate for the prevention of contrast-induced nephropathy: a meta-analysis of 17 randomized trials. International Urology and Nephrology, 2009, 41, 617-627.	1.4	70
368	Trace elements in end-stage renal disease – unfamiliar territory to be revealed. BMC Nephrology, 2009, 10, 12.	1.8	13
369	Systematic review of the evidence underlying the association between mineral metabolism disturbances and risk of all-cause mortality, cardiovascular mortality and cardiovascular events in chronic kidney disease. Nephrology Dialysis Transplantation, 2009, 24, 1506-1523.	0.7	189
370	Blood pressure in dialysis patients—look before we leap. Lancet, The, 2009, 373, 1945.	13.7	2
371	Statin treatment for dyslipidemia in chronic kidney disease and renal transplantation: a review of the evidence. Journal of Nephrology, 2009, 22, 598-609.	2.0	19
372	Mineral and bone disorder after renal transplantation: a review. International Urology and Nephrology, 2008, 40, 171-184.	1.4	22
373	Dyspepsia in Turkish patients on continuous ambulatory peritoneal dialysis. International Urology and Nephrology, 2008, 40, 211-217.	1.4	5
374	Magnesium supplementation helps to improve carotid intima media thickness in patients on hemodialysis. International Urology and Nephrology, 2008, 40, 1075-1082.	1.4	140
375	Dialysis or not in the very elderly ESRD patient. International Urology and Nephrology, 2008, 40, 1127-1132.	1.4	5
376	Calcium and the saga of the binders: accumulating controversy, or building consensus?. International Urology and Nephrology, 2008, 40, 1009-1014.	1.4	5
377	Biosimilars and biopharmaceuticals: what the nephrologists need to knowa position paper by the ERA-EDTA Council. Nephrology Dialysis Transplantation, 2008, 23, 3731-3737.	0.7	62
378	Causes and Mechanisms of Nondipping Hypertension. Clinical and Experimental Hypertension, 2008, 30, 585-597.	1.3	65

#	Article	IF	CITATIONS
379	Renal Anemia: Comparing Current Eastern and Western European Management Practice (ORAMA). Renal Failure, 2008, 30, 267-276.	2.1	11
380	Anaemia management in patients with chronic kidney disease: a position statement by the Anaemia Working Group of European Renal Best Practice (ERBP). Nephrology Dialysis Transplantation, 2008, 24, 348-354.	0.7	178
381	European best practice quo vadis? From European best practice guidelines (EBPG) to European renal best practice (ERBP). Nephrology Dialysis Transplantation, 2008, 23, 2162-2166.	0.7	59
382	Stimulating Erythropoiesis: Future Perspectives. Kidney and Blood Pressure Research, 2008, 31, 234-246.	2.0	19
383	The impact of acute kidney injury on short-term survival in an Eastern European population with stroke. Nephrology Dialysis Transplantation, 2008, 23, 2228-2234.	0.7	72
384	Endorsement of the Kidney Disease Improving Global Outcomes (KDIGO) hepatitis C guidelines: a European Renal Best Practice (ERBP) position statement. Nephrology Dialysis Transplantation, 2008, 24, 719-727.	0.7	41
385	Factors affecting the quality of life of haemodialysis patients from Romania: a multicentric study. Nephrology Dialysis Transplantation, 2008, 24, 626-629.	0.7	58
386	Current management of secondary hyperparathyroidism: a multicenter observational study (COSMOS). Journal of Nephrology, 2008, 21, 290-8.	2.0	21
387	Negative outcome studies in end-stage renal disease: how dark are the storm clouds?. Nephrology Dialysis Transplantation, 2007, 23, 56-61.	0.7	20
388	Relation between Serum Calcium, Phosphate, Parathyroid Hormone and â€~Nondipper' Circadian Blood Pressure Variability Profile in Patients with Normal Renal Function. American Journal of Nephrology, 2007, 27, 516-521.	3.1	23
389	Causes and Consequences of Increased Arterial Stiffness in Chronic Kidney Disease Patients. Kidney and Blood Pressure Research, 2007, 30, 97-107.	2.0	77
390	Relation between Serum Thyroid Hormone and â€~Nondipper' Circadian Blood Pressure Variability. Kidney and Blood Pressure Research, 2007, 30, 416-420.	2.0	22
391	VASCULAR CALCIFICATION IN PATIENTS WITH KIDNEY DISEASE: Introduction: The Binders Wars 1987-2007: Double Decades of Denial, Doubt, Delay. Seminars in Dialysis, 2007, 20, 101-102.	1.3	1
392	Direct renin inhibitors: the dawn of a new era, or just a variation on a theme?. Nephrology Dialysis Transplantation, 2007, 22, 2435-2439.	0.7	30
393	Renal corpuscle morphometry with increased reliability and high level of automation. Pathology Research and Practice, 2007, 203, 9-20.	2.3	7
394	VASCULAR CALCIFICATION IN PATIENTS WITH KIDNEY DISEASE: Vascular Calcification—A New Window on the Cardiovascular System: Role of Agents Used to Manipulate Skeletal Integrity. Seminars in Dialysis, 2007, 20, 158-169.	1.3	11
395	VASCULAR CALCIFICATION IN PATIENTS WITH KIDNEY DISEASE: Final Word: The Binders Wars 2007-2017: "The Truth is Out There Somewhere…― Seminars in Dialysis, 2007, 20, 170-171.	1.3	1
396	Treatment of Proliferative Lupus Nephritis—A Critical Approach. Seminars in Arthritis and Rheumatism, 2007, 36, 224-237.	3.4	19

#	Article	IF	CITATIONS
397	Acute liver failure due to leptospirosis successfully treated with MARS (molecular adsorbent) Tj ETQq1 1 0.78431	4 fgBT /Ov	verlock 10 T
398	Current dilemmas in inhibiting the renin–angiotensin system: do not forget real life. International Urology and Nephrology, 2007, 39, 571-576.	1.4	8
399	Effect of treatment of hyperuricemia with allopurinol on blood pressure, creatinine clearence, and proteinuria in patients with normal renal functions. International Urology and Nephrology, 2007, 39, 1227-1233.	1.4	276
400	Sleep disorders: a systematic review of an emerging major clinical issue in renal patients. International Urology and Nephrology, 2007, 39, 1217-1226.	1.4	65
401	Through the looking glass: the protein science of biosimilars. Clinical and Experimental Nephrology, 2007, 11, 191-195.	1.6	15
402	The protein science of biosimilars. Nephrology Dialysis Transplantation, 2006, 21, v4-v8.	0.7	93
403	The Success Story of Peritoneal Dialysis in Romania: Analysis of Differences in Mortality by Dialysis Modality and Influence of Risk Factors in a National Cohort. Peritoneal Dialysis International, 2006, 26, 266-275.	2.3	18
404	Sirolimus - Challenging Current Perspectives. Therapeutic Drug Monitoring, 2006, 28, 577-584.	2.0	42
405	Posttransplantation Anemia in Adult Renal Allograft Recipients: Prevalence and Predictors. Transplantation, 2006, 81, 1112-1118.	1.0	104
406	The epidemics of cardiovascular disease in elderly patients with chronic kidney disease – Two facets of the same problem. International Urology and Nephrology, 2006, 38, 371-379.	1.4	13
407	Anemia After Renal Transplantation. American Journal of Kidney Diseases, 2006, 48, 519-536.	1.9	72
408	Increased arterial stiffness in children on haemodialysis. Nephrology Dialysis Transplantation, 2006, 21, 729-735.	0.7	101
409	ls it time for spironolactone therapy in dialysis patients?. Nephrology Dialysis Transplantation, 2006, 21, 854-858.	0.7	27
410	Post-transplantation anaemia in adult and paediatric renal allograft recipients—Guy's Hospital experience. Nephrology Dialysis Transplantation, 2006, 21, 1974-1980.	0.7	25
411	Arterial wave reflections and mortality in haemodialysis patients—only relevant in elderly, cardiovascularly compromised?. Nephrology Dialysis Transplantation, 2006, 21, 2859-2866.	0.7	60
412	Epidemiology of renal disease in Romania: a 10 year review of two regional renal biopsy databases. Nephrology Dialysis Transplantation, 2006, 21, 419-424.	0.7	127
413	Cardiovascular disease in haemodialysis and peritoneal dialysis: arguments pro haemodialysis. Nephrology Dialysis Transplantation, 2006, 22, 59-63.	0.7	14
414	Anaemia after Renal Transplantation – Role of Immunosuppressive Drugs and a Pathophysiological Appraisal. Nephron Clinical Practice, 2006, 104, c69-c74.	2.3	7

#	Article	IF	CITATIONS
415	The success story of peritoneal dialysis in Romania: analysis of differences in mortality by dialysis modality and influence of risk factors in a national cohort. Peritoneal Dialysis International, 2006, 26, 266-75.	2.3	10
416	Serial echocardiographic changes in patients on hemodialysis: an evaluation of guideline implementation. Journal of Nephrology, 2006, 19, 783-93.	2.0	20
417	Analysis of safety and efficacy of pegylated-interferon alpha-2a in hepatitis C virus positive hemodialysis patients: results from a large, multicenter audit. Journal of Nephrology, 2006, 19, 794-801.	2.0	42
418	Dynamics of the Circadian Blood Pressure Profiles after Renal Transplantation. Transplantation, 2005, 80, 1168-1173.	1.0	30
419	Intradialytic changes in reflective properties of the arterial system during a single hemodialysis session. Hemodialysis International, 2005, 9, 376-382.	0.9	18
420	Acute effect of CyA A (Neoral®) on large artery hemodynamics in renal transplant patients. Kidney International, 2005, 67, 732-737.	5.2	12
421	Arterial Stiffness in Renal Patients: An Update. American Journal of Kidney Diseases, 2005, 45, 965-977.	1.9	138
422	Systemic Vasculitis: Still a Challenging Disease. American Journal of Kidney Diseases, 2005, 46, 173-185.	1.9	25
423	The Influence of Dialytic Modality on Arterial Stiffness, Pulse Wave Reflections, and Vasomotor Function. Peritoneal Dialysis International, 2004, 24, 365-372.	2.3	40
424	Illness representations and quality of life scores in haemodialysis patients. Nephrology Dialysis Transplantation, 2004, 19, 2078-2083.	0.7	79
425	Optimal composition of the dialysate, with emphasis on its influence on blood pressure. Nephrology Dialysis Transplantation, 2004, 19, 785-796.	0.7	82
426	Hypertension and cardiovascular risk assessment in dialysis patients. Nephrology Dialysis Transplantation, 2004, 19, 1058-1068.	0.7	66
427	Nephrology and renal replacement therapy in Romaniatransition still continues (Cinderella story) Tj ETQq1 1 0.7	784314 rg 0.7	BT/Overlock
428	Cardiovascular disease in renal allograft recipients is associated with elevated sialic acid or markers of inflammation. Clinical Transplantation, 2004, 18, 201-204.	1.6	26
429	Coronary artery calcification and aortic pulse wave velocity in chronic kidney disease patients. Kidney International, 2004, 65, 1790-1794.	5.2	149
430	Vascular calcification: A stiff challenge for the nephrologist. Kidney International, 2004, 66, 1315-1333.	5.2	140
431	HYPERTENSION IN HEMODIALYSIS PATIENTS: Ambulatory Blood Pressure Monitoring in Hemodialysis Patients: A Critique and Literature Review. Seminars in Dialysis, 2004, 17, 255-259.	1.3	6
432	Systolic Blood Pressure Diurnal Variation is Not a Predictor of Renal Target Organ Damage in Kidney Transplant Recipients. American Journal of Transplantation, 2004, 4, 244-247.	4.7	15

#	Article	IF	CITATIONS
433	Insights from ambulatory blood pressure monitoring: diagnosis of hypertension and diurnal blood pressure in renal transplant recipients. Transplantation, 2004, 77, 849-853.	1.0	50
434	Haemodialysis acutely improves endothelium-independent vasomotor function without significantly influencing the endothelium-mediated abnormal response to a Â2-agonist. Nephrology Dialysis Transplantation, 2004, 19, 637-643.	0.7	26
435	Successful use of Molecular Absorbent Regenerating System (MARS) dialysis for the treatment of fulminant hepatic failure in children accidentally poisoned by toxic mushroom ingestion. Liver International, 2003, 23, 21-27.	3.9	55
436	A retrospective 5-year study in Moldova of acute renal failure due to leptospirosis: 58 cases and a review of the literature. Nephrology Dialysis Transplantation, 2003, 18, 1128-1134.	0.7	74
437	Recent insights from studies using ambulatory blood pressure monitoring in patients with renal disease. Current Opinion in Nephrology and Hypertension, 2003, 12, 645-648.	2.0	5
438	Ambulatory blood pressure monitoring in renal transplantation: should ABPM be routinely performed in renal transplant patients?. Transplantation, 2003, 76, 1640-1642.	1.0	31
439	The challenge of cardiovascular risk factors in end-stage renal disease. Journal of Nephrology, 2003, 16, 476-86.	2.0	31
440	Haemodialysis increases QTc interval but not QTc dispersion in ESRD patients without manifest cardiac disease. Nephrology Dialysis Transplantation, 2002, 17, 2170-2177.	0.7	94
441	How important and how treatable is vascular stiffness as a cardiovascular risk factor in renal failure?. Nephrology Dialysis Transplantation, 2002, 17, 965-969.	0.7	16
442	Ambulatory blood pressure monitoring: an essential tool for blood pressure assessment in uraemic patients. Nephrology Dialysis Transplantation, 2002, 17, 1737-1741.	0.7	19
443	Ambulatory blood pressure measurement in the renal patient. Current Hypertension Reports, 2002, 4, 369-376.	3.5	10
444	The reproducibility of the circadian BP rhythm in treated hypertensive patients with polycystic kidney disease and mild chronic renal impairmenta prospective ABPM study. Journal of Nephrology, 2002, 15, 497-506.	2.0	11
445	Coronary artery disease in uremia: Etiology, diagnosis, and therapy. Kidney International, 2001, 60, 2059-2078.	5.2	91
446	Analysis of the effect of hemodialysis on peripheral and central arterial pressure waveforms. Kidney International, 2000, 57, 2634-2643.	5.2	94
447	Inaccuracy of clinical phenotyping parameters for hypertensive nephrosclerosis. Nephrology Dialysis Transplantation, 2000, 15, 1801-1807.	0.7	66
448	Reduced blood pressure diurnal variability as a risk factor for progressive left ventricular dilatation in hemodialysis patients. American Journal of Kidney Diseases, 2000, 35, 617-623.	1.9	65
449	Relationships between blood pressure variability and left ventricular parameters in haemodialysis and renal transplant patients. Nephrology, 1998, 4, 87-93.	1.6	12
450	Relationships between blood pressure variability and left ventricular parameters in haemodialysis and renal transplant patients. Nephrology, 1998, 4, 87-93.	1.6	1

#	Article	IF	CITATIONS
451	Analysis of Blood Pressure Variability Derived from Ambulatory Blood Pressure Monitoring in 92 Uraemic Patients. Contributions To Nephrology, 1996, 119, 157-160.	1.1	7